AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
Dec 5 (Reuters) - AstraZeneca Plc AZN.L and Merck & Co Inc MRK.N said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ovarian cancer.
The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo.
Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr)
((Aakash.B@thomsonreuters.com; within the U.S. +16462238780, outside the U.S. +91 80 67491576; Twitter: @JagadeeshAakash;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Latest Markets Videos
- Shipping Group Maersk to Buy U.S. Warehousing and Distribution Firm
- Canada tweaks mortgage stress test in move that could boost housing market
- EU adds Seychelles, Cayman Islands, Panama to tax haven blacklist, spares Turkey
- EXCLUSIVE-SmileDirectClub’s top dentist risks losing license in California crackdown